The Disposable Insulin-Delivery Device Market is expected to be worth US$ 14,585.6 million in 2022, with a compound annual growth rate (CAGR) of 7.7% between 2022 and 2032, for a total market worth US$ 32,887.5 million. This expansion is mostly driven by an increase in diabetes-related health spending in developing countries.
According to the International Diabetes Federation (IDF), one-tenth of the total population affected by diabetes has Type 1, and 10% of these individuals do not currently use insulin delivery devices, implying that the Disposable Insulin-Delivery Device market has significant potential for growth during the forecast period.
Grab a visually stunning report with related graphs and charts as a bonus. @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5059
Pens are currently the most prevalent insulin delivery technology, accounting for more than 36% of the market when compared to syringes, pumps, and jet injectors. Pens’ design and ease of use have contributed to their widespread use. NovoPen is now the market leader, with a memory function as an extra bonus.
The principal end-user of Disposable Insulin-Delivery Devices is home care, which accounts for more than 45% of the market. The cost-effectiveness of home care over hospital treatment is a major contributor to this trend. Furthermore, the portability of these gadgets adds to their use for home care application. Future industry Insights did an in-depth analysis of the Disposable Insulin-Delivery Device industry, encompassing both micro and macro variables, in their latest market study titled ‘Disposable Insulin-Delivery Device Market.’
Key Takeaways from Disposable Insulin-Delivery Device Market
- North America has a 33% market share. Rising diabetes rates, credible government programmes, and the emergence of many disposable insulin delivery device manufacturers could all contribute to this. Diabetes affects more than 37 million people in the United States, according to the CDC.
- As a result of advances in healthcare infrastructure throughout Europe, Europe today controls 29% of the market. Diabetes was diagnosed in about 32 million persons in the EU in 2019.
- Rising diabetes awareness is one of the key forces driving the Disposable Insulin-Delivery Device market in the Asia-Pacific region, and this trend is expected to continue.
Discount Extravaganza: Unleashing Unbeatable Savings. Contact Us for a Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-5059
Key Players:
- Animas Corporation
- F. Hoffmann-La Roche AG
- Insulet Corporation
- Medtronic Plc.
- Valeritas, Inc.,
- Tandem Diabetes Care, Inc.
- Johnson & Johnson
- Beta Bionics Inc.
- Abbott Laboratories
- Becton Dickinson & Co.
- EyeSense GmbH
Competitive Landscape
- In February 2022, Abbott announced a partnership with Fitterfly, Healthifyme, Zyla Health, 1MG, GOQii, PharmEasy, Sugar.fit, and BeatO as a step towards holistic diabetes control treatment. Abbott provides glucose monitoring solutions to over 8 million diabetes patients through collaborations, with 6.5 million having access to 1MG and PharmEasy.
- Insulet Corp. announced in January 2022 that the new Omnipod 5 system had been approved by the US FDA, introducing it into the field of AID (automated insulin delivery).
- In March 2022, Novo Nordisk announced the availability of two smart linked insulin pens called ‘NovoPen Echo Plus’ and ‘NovoPen 6’ for patients receiving Novo Nordisk insulin in the UK.
- Sanofi and Roche will collaborate in November 2021 to increase the usage of disposable insulin pens. Local players are also being approached in order to expand market penetration.
“A large chunk of population is contracting diabetes, which asks for Disposable Insulin-Delivery Devices”, thereby accelerating the market for the same”, says an analyst from Future Market Insights.
We Offer tailor-made Solutions to fit Your Requirements, Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-5059
What does the Report have at its discretion?
- In its latest analysis, Future Market Insights provides an exclusive perspective and numerous real-time data on the Disposable Insulin-Delivery Device market, presenting historical demand assessments from 2016 to 2021 and predictions from 2022 to 2032.
- The study is divided into three sections: product type (disposable insulin-delivery pumps, disposable insulin-delivery patches, disposable insulin-delivery pens, and disposable insulin-delivery syringes), illness indication (type I and type II diabetes), and distribution channel (hospital pharmacies, retail pharmacies, online sales, and diabetes clinics).
- With an increase in the number of diabetic patients as a result of obesity, ageing, and sedentary lifestyles, the global Disposable Insulin-Delivery Device market is poised to make waves in the healthcare industry in the next years.
Want more insights:
In North America, the market is mature and dominated by established players such as Novo Nordisk and Eli Lilly. The increasing prevalence of diabetes, favorable reimbursement policies, and the availability of Advanced Insulin Delivery Technologies have been the key drivers of market growth in this region.
Key Segments Profiled in the Disposable Insulin-Delivery Device Market
Disposable Insulin-Delivery Device Market by Product Type:
- Disposable Insulin-Delivery Pumps
- Disposable Insulin-Delivery Patches
- Disposable Insulin-Delivery Pens
- Disposable Insulin-Delivery Syringes
Disposable Insulin-Delivery Device Market by Disease Indication:
- Disposable Insulin-Delivery Devices for Type I Diabetes
- Disposable Insulin-Delivery Devices for Type II Diabetes
Disposable Insulin-Delivery Device Market by Distribution Channel:
- Disposable Insulin-Delivery Devices Sales via Hospital Pharmacies
- Disposable Insulin-Delivery Devices Sales via Retail Pharmacies
- Disposable Insulin-Delivery Devices Sales via Online Sales
- Disposable Insulin-Delivery Devices Sales via Diabetes Clinics
Explore Wide-ranging Coverage of FMI’s Healthcare Landscape:
Amniotic Membranes Market: The global amniotic membranes market size is likely to touch a valuation of around US$ 1.4 Bn in 2022. Further, with rising adoption of amniotic membranes for various purposes in ophthalmology, the total sales of amniotic membranes are slated to grow at an impressive CAGR of 9.0% between 2022 and 2028, totalling over US$ 2.3 Bn by the end of 2028.
Digital Radiography Detectors Market: The digital radiography detectors market is valued at US$ 2.13 Bn in 2022. The market is advancing at an average pace with a CAGR of 6.1% through 2026 to reach a valuation of US$ 2.7 Bn. The worldwide market for digital radiography detectors is highly concentrated, with large competitors such as Varex Imaging Corporation and Trixell accounting for about 47% of the market share.
Sepsis Diagnostics Market: The global sepsis diagnostics market is expected to record a CAGR of 8.1% between 2023 and 2033. In 2023, the market is estimated to be valued at US$ 561.2 million. The valuation is expected to cross US$ 1.2 billion by 2033
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
